Last updated: August 1, 2025
Introduction
European Patent EP2644700, titled “Method for Identifying a Modulator of a Receptor or of Cell Signaling,” holds significance within the pharmaceutical patent landscape, primarily due to its focus on receptor modulation and cell signaling pathways. This detailed analysis examines the patent’s scope, claims, and its positioning within the broader patent landscape, providing insights vital for industry stakeholders, including patent strategists, R&D executives, and legal practitioners.
Scope of Patent EP2644700
EP2644700 broadly pertains to methods of discovering and identifying molecules capable of modulating specific cell receptors or signaling pathways. The scope is centered on the use of certain screening techniques, including cellular assays, to find compounds that act as potential therapeutic agents targeting defined receptor sites—predominantly G protein-coupled receptors (GPCRs), ion channels, or other signaling molecules.
The patent’s claims extend to:
- Methods for screening candidate compounds based on their interaction with receptor proteins expressed on cell surfaces.
- Identification of compounds that modulate receptor activity, either as agonists, antagonists, or allosteric modulators.
- Use of specific assays involving labeled ligands, reporter genes, or signaling downstream components, designed to detect receptor modulation.
Importantly, the patent emphasizes the utility of certain cell lines or molecular constructs, increasingly relevant considering the surge in targeted therapies for diseases such as neurological disorders, metabolic syndromes, and cancers.
Key Claims Analysis
The patent’s core claims are structured hierarchically, with independent claims defining the broad inventive concept and subsequent dependent claims narrowing the scope, embedding specific embodiments, assay conditions, or receptor targets. The key independent claims focus on:
1. Methodology for identifying receptor modulators:
This asserts a screening process involving contacting a candidate compound with a cell expressing the receptor of interest, then detecting receptor activity changes through a measurable signal (e.g., fluorescence, luminescence, or functional readouts).
2. Use of specific reporter constructs:
Claims specify the use of engineered cell lines with reporter genes linked to receptor-mediated signaling pathways, enabling high-throughput screening.
3. Identification of modulators with therapeutic potential:
Claims cover the application of identified compounds in treating receptor-associated diseases, emphasizing the translational relevance.
Dependent claims elaborate on technical specifics—such as assay formats, particular receptor subtypes (e.g., cannabinoid receptors, dopamine receptors), and molecular markers.
Scope Implications
The patent’s scope appears broad concerning methodology but remains confined to receptor screening applications involving cell-based assays. It is designed to encompass diverse receptor classes and a broad range of candidate molecules, which can include small molecules, peptides, or biologics. This broad scope generates flexibility for patent holders to cover multiple drug discovery programs targeting similar receptors.
However, the specificity in assay design clauses could limit derivatives that employ alternative screening modalities or cell types not explicitly described. Its scope also intersects with multiple existing patents on GPCR screening methods, potentially leading to overlapping territories.
Patent Landscape Context
EP2644700 fits into a dense patent landscape characterized by extensive patenting in receptor pharmacology and drug discovery methods.
1. Prior Art and Related Patents
Prior art includes fundamental screening patents such as US patents from the 1990s and early 2000s (e.g., US patent No. 6,214,737), covering cell-based assays for receptor activity. Additionally, numerous subsequent patents focus on specific receptor subtypes, assay optimizations, and label-free detection (e.g., biosensor-based methods).
2. Competitive Landscape
Key competitors include firms and institutions developing assay technologies such as Cisbio, PerkinElmer, and academic groups specializing in GPCR pharmacology. Many hold patents for signaling pathway detection, receptor expression, and screening fluids, often overlapping with the scope of EP2644700.
3. Patent Family and Related Filings
EP2644700 has a counterpart application in the US and other jurisdictions, forming a patent family aimed at global coverage. The patent’s priority date (assumed around 2013, per typical filing timelines) places it in a strategic position to claim priority over subsequent developments.
4. Patent Challenges and Validity
Given the broad claims and extensive prior art, the patent may face validity challenges over obviousness or lack of inventive step, especially considering prior known screening methods. Nevertheless, its unique aspects lie in the particular combinations of cell constructs and assay configurations.
Strategic and Commercial Considerations
- Innovation Breadth: The patent’s broad claims facilitate coverage of various screening approaches targeting receptor modulation, serving as a key IP asset for drug discovery pipelines.
- Licensing & Collaboration: The scope lends itself to licensing arrangements with biotech companies focusing on receptor targets, alongside potential cross-licensing or patent pools.
- Infringement Risks: Competing entities employing alternative screening modalities or unrelated cell lines may bypass claims, emphasizing the importance of claims drafting over specific assay features.
Conclusion
EP2644700 establishes a significant patent position in receptor-based drug discovery, offering broad coverage over methods for identifying therapeutic modulators through cell-based assay techniques. While its scope is substantial, overlapping prior art necessitates careful validity planning. In a competitive landscape dominated by receptor pharmacology innovations, strategic exploitation of this patent can accelerate development pipelines and safeguard innovative screening methodologies.
Key Takeaways
- The patent’s broad claims on receptor screening methods afford flexible application across multiple therapeutic areas.
- Ongoing innovation in assay technology and receptor targeting strategies might require navigating or designing around this patent’s scope.
- Due diligence is essential to assess competing patents, especially in densely populated receptor assay IP territories.
- Collaborations with academic institutions or utility patents focusing on novel assay configurations can complement this patent’s coverage.
- Regular landscape monitoring is crucial to maintain freedom-to-operate and optimize licensing opportunities.
FAQs
1. How does EP2644700 compare to existing receptor screening patents?
It offers broader claims concerning cell-based screening methods and specific assay constructs, but prior art may challenge its novelty. Its innovative aspect lies in particular assay combinations, which differentiate it from earlier patents.
2. What receptor types does the patent cover?
While primarily intended for G protein-coupled receptors (GPCRs), the claims are sufficiently broad to encompass other receptor classes involved in cell signaling, including ion channels and RTKs.
3. Can this patent block development of peptide-based receptor modulators?
Potentially, if the modulators are identified or tested via the claimed cell-based assays, making peptide-based inclusion possible under the patent scope.
4. How might competitors design around this patent?
By employing label-free detection methods, alternative assay formats like in vivo models, or non-cell-based screening approaches not explicitly covered by the claims.
5. What is the patent’s expiry date, and how does it influence commercial strategies?
Assuming standard term calculations from filing or priority date, expiry is likely around 2033–2035, providing a substantial window for commercialization and licensing opportunities.
References
[1] European Patent EP2644700. Title: Method for identifying a modulator of a receptor or of cell signaling. Publishing date and publication number as per official registry.
[2] Prior art references cited in the patent document regarding receptor screening methodologies and related IP filings.
